RU2017139718A - Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток - Google Patents
Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток Download PDFInfo
- Publication number
- RU2017139718A RU2017139718A RU2017139718A RU2017139718A RU2017139718A RU 2017139718 A RU2017139718 A RU 2017139718A RU 2017139718 A RU2017139718 A RU 2017139718A RU 2017139718 A RU2017139718 A RU 2017139718A RU 2017139718 A RU2017139718 A RU 2017139718A
- Authority
- RU
- Russia
- Prior art keywords
- cell
- agent
- mutation
- cancer
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 5
- 201000010099 disease Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 230000001413 cellular effect Effects 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 101150048834 braF gene Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 4
- 230000030833 cell death Effects 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 229940125431 BRAF inhibitor Drugs 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 230000009643 growth defect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Агент, индуцирующий клеточную гибель, для клетки, имеющей мутацию в гене BRAF, включающий лекарственное средство, подавляющее GST-π, в качестве активного компонента.
2. Агент, подавляющий клеточный рост для клетки, имеющей мутацию в гене BRAF, включающий лекарственное средство, подавляющее GST-π, в качестве активного компонента.
3. Агент по п. 1 или 2, где мутация представляет собой мутацию V600E.
4. Агент по п. 1 или 2, где клетка, имеющая мутацию в гене BRAF, представляет собой клетку, устойчивую к ингибитору BRAF.
5. Агент по п. 1 или 2, где лекарственное средство представляет собой вещество, выбранное из группы, состоящей из молекул РНК-интерференции, рибозимов, антисмысловых нуклеиновых кислот, ДНК/РНК-химерных полинуклеотидов и векторов, экспрессирующих по меньшей мере одно из них.
6. Агент по п. 1 или 2, где клетка, имеющая мутацию в гене BRAF, представляет собой раковую клетку, высоко экспрессирующую GST-π.
7. Фармацевтическая композиция для терапии заболевания, вызванного дефектом роста клетки, имеющей мутацию в гене BRAF, содержащая агент по любому из пп. 1-6.
8. Фармацевтическая композиция по п. 7, где заболевание представляет собой рак.
9. Фармацевтическая композиция по п. 8, где рак представляет собой рак, высоко экспрессирующий GST-π.
10. Фармацевтическая композиция по п. 8, где раком является колоректальный рак или меланома.
11. Способ скрининга агента, индуцирующего клеточную гибель, и/или агента, подавляющего клеточный рост для клетки, имеющей мутацию в гене BRAF, включающий выбор лекарственного средства, подавляющего GST-π.
12. Способ скрининга по п. 11, включающий
этап контактирования тестируемого вещества с раковой клеткой,
этап измерения уровня экспрессии GST-π в клетке и этап выбора тестируемого вещества в качестве лекарственного средства, подавляющего GST-π, когда уровень экспрессии снижен по сравнению со случаем, измеренным в отсутствие тестируемого вещества.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015084286 | 2015-04-16 | ||
| JP2015-084286 | 2015-04-16 | ||
| JP2016-078710 | 2016-04-11 | ||
| JP2016078710A JP6864990B2 (ja) | 2015-04-16 | 2016-04-11 | Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 |
| PCT/JP2016/062090 WO2016167340A1 (ja) | 2015-04-16 | 2016-04-15 | Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017139718A true RU2017139718A (ru) | 2019-05-16 |
| RU2017139718A3 RU2017139718A3 (ru) | 2019-10-02 |
| RU2760835C2 RU2760835C2 (ru) | 2021-11-30 |
Family
ID=57127072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017139718A RU2760835C2 (ru) | 2015-04-16 | 2016-04-15 | Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN116271056A (ru) |
| ES (1) | ES2978957T3 (ru) |
| PT (1) | PT3284481T (ru) |
| RU (1) | RU2760835C2 (ru) |
| WO (1) | WO2016167340A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4245758A3 (en) | 2017-10-26 | 2023-12-20 | Xynomic Pharmaceuticals, Inc. | Crystalline salts of a b-raf kinase inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050019918A1 (en) * | 2003-06-03 | 2005-01-27 | Hidetoshi Sumimoto | Treatment of cancer by inhibiting BRAF expression |
| EP2724729B1 (en) * | 2011-06-21 | 2018-12-26 | Nitto Denko Corporation | Apoptosis-inducing agent |
| JP6340162B2 (ja) * | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| WO2014147573A2 (en) * | 2013-03-21 | 2014-09-25 | Novartis Ag | Combination therapy |
| GB201312155D0 (en) * | 2013-07-05 | 2013-08-21 | Ucl Business Plc | Therapeutic invention |
-
2016
- 2016-04-15 PT PT167801315T patent/PT3284481T/pt unknown
- 2016-04-15 ES ES16780131T patent/ES2978957T3/es active Active
- 2016-04-15 CN CN202310302851.0A patent/CN116271056A/zh active Pending
- 2016-04-15 RU RU2017139718A patent/RU2760835C2/ru active
- 2016-04-15 WO PCT/JP2016/062090 patent/WO2016167340A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN116271056A (zh) | 2023-06-23 |
| WO2016167340A1 (ja) | 2016-10-20 |
| PT3284481T (pt) | 2024-06-04 |
| RU2017139718A3 (ru) | 2019-10-02 |
| RU2760835C2 (ru) | 2021-11-30 |
| ES2978957T3 (es) | 2024-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miller et al. | Cytoplasmic DNA: sources, sensing, and role in aging and disease | |
| Thapar | Regulation of DNA double-strand break repair by non-coding RNAs | |
| Du et al. | Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling | |
| Hudgins et al. | Age-and tissue-specific expression of senescence biomarkers in mice | |
| Evangelou et al. | Escape from senescence: molecular basis and therapeutic ramifications | |
| Chacon-Cabrera et al. | MicroRNA expression and protein acetylation pattern in respiratory and limb muscles of Parp-1−/− and Parp-2−/− mice with lung cancer cachexia | |
| Porritt et al. | Photothrombosis-induced infarction of the mouse cerebral cortex is not affected by the Nrf2-activator sulforaphane | |
| Xie et al. | NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3 | |
| EA201790420A1 (ru) | Средства, представляющие собой модифицированную двухнитевую рнк | |
| JP2012050449A5 (ru) | ||
| JP2016500110A5 (ru) | ||
| WO2014022826A3 (en) | Biomarker associated with risk of melanoma reoccurrence | |
| JP2011162558A5 (ru) | ||
| Phua et al. | Renal stromal mi RNA s are required for normal nephrogenesis and glomerular mesangial survival | |
| Park et al. | Mammalian SWI/SNF chromatin remodeling complexes are required to prevent apoptosis after DNA damage | |
| RU2017126612A (ru) | Средство, индуцирующее гибель клеток, средство, ингибирующее рост клеток, и фармацевтическая композиция для лечения заболевания, вызванного аномальным клеточным ростом | |
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| WO2015048793A3 (en) | Nucleic acid biomarker and use thereof | |
| EP3775288B1 (en) | Mirnas for treatment and in vitro diagnosis of drug resistant tumors | |
| BR112014026440A2 (pt) | assays, methods and apparatus for assessing rna disruption | |
| Tang et al. | Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer | |
| AR101440A1 (es) | MÚLTIPLES ARNi DIRIGIDOS PARA EL TRATAMIENTO DEL CÁNCER | |
| Du et al. | Role of miR-199b-5p in regulating angiogenesis in mouse myocardial microvascular endothelial cells through HSF1/VEGF pathway | |
| Ladd | New insights into the role of RNA-binding proteins in the regulation of heart development | |
| EA201792261A1 (ru) | Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы |